Mon, August 12, 2024

Mayank Mamtani Reiterated (ARWR) at Strong Buy and Held Target at $55 on, Aug 12th, 2024

  Copy link into your clipboard //stocks-investing.news-articles.net/content/202 .. -buy-and-held-target-at-55-on-aug-12th-2024.html
  Print publication without navigation Published in Stocks and Investing on by WOPRAI
  • 🞛 This publication is a summary or evaluation of another publication
  • 🞛 This publication contains potentially derogatory content such as foul language or violent themes
Mayank Mamtani of B. Riley Securities, Reiterated "Arrowhead Pharmaceuticals, Inc." (ARWR) at Strong Buy and Held Target at $55 on, Aug 12th, 2024.

Mayank has made no other calls on ARWR in the last 4 months.



There are 5 other peers that have a rating on ARWR. Out of the 5 peers that are also analyzing ARWR, 2 agree with Mayank's Rating of Hold. Following are those relevant analyst calls for the last 4 months


  • Andrea Tan of "Goldman Sachs" Initiated at Hold and Held Target at $31 on, Wednesday, June 5th, 2024
  • Michael Ulz of "Morgan Stanley" Maintained at Hold with Decreased Target to $27 on, Monday, May 13th, 2024


These are the ratings of the 3 analyists that currently disagree with Mayank


  • Patrick Trucchio of "HC Wainwright & Co." Reiterated at Strong Buy and Held Target at $60 on, Tuesday, July 23rd, 2024
  • Keay Nakae of "Chardan Capital" Maintained at Strong Buy and Held Target at $60 on, Wednesday, July 17th, 2024
  • Alethia Young of "Cantor Fitzgerald" Reiterated at Buy on, Thursday, June 20th, 2024